DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01700075

PCSAM

CompletedPhase 4

Physical and Chemical Study of Atherosclerosis Mechanisms

Comparative Physical and Chemical Study of the Mechanisms of Atherosclerosis With Development of Concept of Treatment and Prevention

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

97

actual

Study population

Cardiovascular disease, Dyslipidemia, Hypertension, Metabolic syndrome, Obesity / overweight

Key I/E criterion

—

Primary endpoint

•Full recovery from atherosclerotic diseases

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01700075
Org study ID0109RK000079

Timeline

Milestones

Study first posted2012-10-04estimated
Last update posted2012-10-04estimated
Study start2009-01 (month precision)
Primary completion2009-12actual (month precision)
Study completion2011-12actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Cardiovascular diseaseDyslipidemiaHypertensionMetabolic syndromeObesity / overweight

Eligibility

Who can enroll

Minimum age26 Years
Maximum age70 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•written informed consent form
•dyslipidemia (HDL <1.0 mmol / l, triglycerides (TG) in plasma ≥ 1,7 mmol / l or cholesterol ≥ 5,6 mmol /l)
•waist circumference ≥ 94.0 cm in men or ≥ 80,0 cm in women,
•BP ≥140/95 mm Hg or a patient is taking antihypertensive medications,
•fasting glucose ≥ 6,1 mmol / l or the patient is taking hypoglycemic agents,
•the possibility of treatment for 6 months and follow-up for 1 year

Exclusion criteria

•Absence of consent form
•Non-compliance of patient to necessary recommendations.
•The presence of mental illness.
•Complete immobilization of a patient (paresis, and paralysis).

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

full recovery from atherosclerotic diseases

Time frame:for 12 months

categorical status, improvement

Secondary/protocol endpoint/low confidence

normalised laboratory and instrumental data

Time frame:for 12 month

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.